Prevention of head and neck squamous cell carcinoma

Removing the "chemo" from "chemoprevention"

Nabil F. Saba, Missak Haigentz, Jan B. Vermorken, Primož Strojan, Paolo Bossi, Alessandra Rinaldo, Robert P. Takes, Alfio Ferlito

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The concept of chemoprevention whereby the use of a systemic agent is intended to halt the carcinogenesis process has been an attractive topic in head and neck squamous cell carcinoma (HNSCC). Yet, despite the significant efforts over the past decades and the substantial gain in knowledge of the biology of premalignant lesions of the head and neck, no tangible indications for chemoprevention have emerged for this disease. The negative results observed in the earlier larger studies using retinoids did not encourage further trials with these agents. Attention has been more recently focused on epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) as well as cyclo-oxygenase 2 (COX-2) inhibitors with early studies showing encouraging responses but rather poor tolerance to therapy. Natural compounds have gained more interest recently given preclinical evidence of activity as well as a low side effect profile. We herein offer a comprehensive overview of the field of chemoprevention in HNSCC with an in depth analysis of the challenges we face and discuss a road map for future directions.

Original languageEnglish (US)
Pages (from-to)112-118
Number of pages7
JournalOral Oncology
Volume51
Issue number2
DOIs
StatePublished - 2015

Fingerprint

Chemoprevention
Cyclooxygenase Inhibitors
Retinoids
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Carcinogenesis
Neck
Head
Carcinoma, squamous cell of head and neck
Therapeutics

Keywords

  • Carcinoma in situ
  • Chemoprevention
  • Head and neck cancer
  • Oral dysplasia
  • Premalignant lesions
  • Second primary tumor

ASJC Scopus subject areas

  • Oncology
  • Oral Surgery
  • Cancer Research

Cite this

Saba, N. F., Haigentz, M., Vermorken, J. B., Strojan, P., Bossi, P., Rinaldo, A., ... Ferlito, A. (2015). Prevention of head and neck squamous cell carcinoma: Removing the "chemo" from "chemoprevention". Oral Oncology, 51(2), 112-118. https://doi.org/10.1016/j.oraloncology.2014.11.002

Prevention of head and neck squamous cell carcinoma : Removing the "chemo" from "chemoprevention". / Saba, Nabil F.; Haigentz, Missak; Vermorken, Jan B.; Strojan, Primož; Bossi, Paolo; Rinaldo, Alessandra; Takes, Robert P.; Ferlito, Alfio.

In: Oral Oncology, Vol. 51, No. 2, 2015, p. 112-118.

Research output: Contribution to journalArticle

Saba, NF, Haigentz, M, Vermorken, JB, Strojan, P, Bossi, P, Rinaldo, A, Takes, RP & Ferlito, A 2015, 'Prevention of head and neck squamous cell carcinoma: Removing the "chemo" from "chemoprevention"', Oral Oncology, vol. 51, no. 2, pp. 112-118. https://doi.org/10.1016/j.oraloncology.2014.11.002
Saba, Nabil F. ; Haigentz, Missak ; Vermorken, Jan B. ; Strojan, Primož ; Bossi, Paolo ; Rinaldo, Alessandra ; Takes, Robert P. ; Ferlito, Alfio. / Prevention of head and neck squamous cell carcinoma : Removing the "chemo" from "chemoprevention". In: Oral Oncology. 2015 ; Vol. 51, No. 2. pp. 112-118.
@article{6bbfed3946c146e6a3a42ddca4f3009e,
title = "Prevention of head and neck squamous cell carcinoma: Removing the {"}chemo{"} from {"}chemoprevention{"}",
abstract = "The concept of chemoprevention whereby the use of a systemic agent is intended to halt the carcinogenesis process has been an attractive topic in head and neck squamous cell carcinoma (HNSCC). Yet, despite the significant efforts over the past decades and the substantial gain in knowledge of the biology of premalignant lesions of the head and neck, no tangible indications for chemoprevention have emerged for this disease. The negative results observed in the earlier larger studies using retinoids did not encourage further trials with these agents. Attention has been more recently focused on epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) as well as cyclo-oxygenase 2 (COX-2) inhibitors with early studies showing encouraging responses but rather poor tolerance to therapy. Natural compounds have gained more interest recently given preclinical evidence of activity as well as a low side effect profile. We herein offer a comprehensive overview of the field of chemoprevention in HNSCC with an in depth analysis of the challenges we face and discuss a road map for future directions.",
keywords = "Carcinoma in situ, Chemoprevention, Head and neck cancer, Oral dysplasia, Premalignant lesions, Second primary tumor",
author = "Saba, {Nabil F.} and Missak Haigentz and Vermorken, {Jan B.} and Primož Strojan and Paolo Bossi and Alessandra Rinaldo and Takes, {Robert P.} and Alfio Ferlito",
year = "2015",
doi = "10.1016/j.oraloncology.2014.11.002",
language = "English (US)",
volume = "51",
pages = "112--118",
journal = "Oral Oncology",
issn = "1368-8375",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - Prevention of head and neck squamous cell carcinoma

T2 - Removing the "chemo" from "chemoprevention"

AU - Saba, Nabil F.

AU - Haigentz, Missak

AU - Vermorken, Jan B.

AU - Strojan, Primož

AU - Bossi, Paolo

AU - Rinaldo, Alessandra

AU - Takes, Robert P.

AU - Ferlito, Alfio

PY - 2015

Y1 - 2015

N2 - The concept of chemoprevention whereby the use of a systemic agent is intended to halt the carcinogenesis process has been an attractive topic in head and neck squamous cell carcinoma (HNSCC). Yet, despite the significant efforts over the past decades and the substantial gain in knowledge of the biology of premalignant lesions of the head and neck, no tangible indications for chemoprevention have emerged for this disease. The negative results observed in the earlier larger studies using retinoids did not encourage further trials with these agents. Attention has been more recently focused on epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) as well as cyclo-oxygenase 2 (COX-2) inhibitors with early studies showing encouraging responses but rather poor tolerance to therapy. Natural compounds have gained more interest recently given preclinical evidence of activity as well as a low side effect profile. We herein offer a comprehensive overview of the field of chemoprevention in HNSCC with an in depth analysis of the challenges we face and discuss a road map for future directions.

AB - The concept of chemoprevention whereby the use of a systemic agent is intended to halt the carcinogenesis process has been an attractive topic in head and neck squamous cell carcinoma (HNSCC). Yet, despite the significant efforts over the past decades and the substantial gain in knowledge of the biology of premalignant lesions of the head and neck, no tangible indications for chemoprevention have emerged for this disease. The negative results observed in the earlier larger studies using retinoids did not encourage further trials with these agents. Attention has been more recently focused on epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) as well as cyclo-oxygenase 2 (COX-2) inhibitors with early studies showing encouraging responses but rather poor tolerance to therapy. Natural compounds have gained more interest recently given preclinical evidence of activity as well as a low side effect profile. We herein offer a comprehensive overview of the field of chemoprevention in HNSCC with an in depth analysis of the challenges we face and discuss a road map for future directions.

KW - Carcinoma in situ

KW - Chemoprevention

KW - Head and neck cancer

KW - Oral dysplasia

KW - Premalignant lesions

KW - Second primary tumor

UR - http://www.scopus.com/inward/record.url?scp=84922489753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922489753&partnerID=8YFLogxK

U2 - 10.1016/j.oraloncology.2014.11.002

DO - 10.1016/j.oraloncology.2014.11.002

M3 - Article

VL - 51

SP - 112

EP - 118

JO - Oral Oncology

JF - Oral Oncology

SN - 1368-8375

IS - 2

ER -